gsk wants to produce relenza in china, page-5

What a great sign. From the brief commentary at the last quarterly GSK said they will increase production to well over 100m by the end of next year. Why?

Here we see talk about building another plant in China. Why?

I suspect there is huge underlying demand from global governments, now that around 60 countries (up from 10 pre swine flu) are stockpiling there simply isn't enough relenza to go around.

We already knew that 2009 CY production was spoken for, I wonder how much of 2010 production is spoken for. Capacity could be over 190m next year, that's big bucks for Biota... dividend, buybacks, expansion of pipeline or whatever, it's going to be an interesting 2010.

And Relenza is just the beginning of the story, I can't wait to see the license package Biota can achieve for BTA798 and Laninamivir.